Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thats correct. boodog I appreciate your and the work of bikmann. So it seems that the whole market is misinformed about ANTH? I´m in ANTH since last august and have already made money with this, no question. But wether sabby nor orbimed will be very amused which direction share price has taken the last time. Even when I trust in ANTH products I dont automatically must trust in their management - and there are my concerns. How often has ANTH released PRs as participant at the one or other healthcare conference? But they never PRed any results from this events, absolutely nothing. Maybe this company is dead? this is not in the sense of any investor
current price reflects worth of this company and their work and this currently is equal zero
they have time until june to bring this stock over 1$ without a R/S. on the other hand why should investors not sell this stock even with a loss when there are myriads of possibilities every day to make quick money with other stocks?
I´ve the feeling the company itself is currently not much interested whether in a higher share price nor to build shareholder value
ho ho ho who has sold for this f....g prices?? :o)
good luck always. no question this stock will go to da moon (from where its coming from) when they release positive results from their clinical trials, as alway money and patience is needed. Nevertheless I´m very often unhappy how they promote their products/company, they must improve. I´ve a very critical sight on this company but also trust in their products. But they also can fail like CLSX - so that is biotech
thanks for the good work
totally agreed, new target 3$
great thanks
hopefully, institutional investors have bought also mid february
all gains this stock has made since mr terwilliger has bought in are lost until today - maybe this will help :o)
for sure only investing in a company with a future
sabby is not dumb and not only engaged in this biotech stock
must be a very succesful presentation today when i have a look at current price developments ;o)
red arrow good for a bargain hunter
good try - and joke. they have (enough) money in cash for this year. sorry for their employees, but next step will be a headcount. alternative they disclose something most positive
exactly prove have shown today
strong action first 100 shares traded so far :o)
price and volume is a joke, as so often. interesting to see if they have to unveil something positive on thursday
trading has just begun
has everybody seen insidertrading? One of directors has bought total of 7.400.000 shares last week and another big buy for today
i´m wondering who´s selling at discount prices, must be extremly out of cash
maybe or not, maybe management is more smart then all of us
what they have also in the worx http://celsion.com/pages/pipeline
Orbimed has also taken "some" bargain shares - like me :o)
TANG CAPITAL PARTNERS LP today has increased its stake in Anthera
why is management not able to wake interest for a takeover of this company instead of a public offering?
not only volume is a joke
great, thanks to all
good for management and other smart people like me to collect again all these cheap shares :o)
wonder why they haven´t PRed something about their participation at the JP Morgan healthcare conference
so whats the benefit for HUSA?
little sign of "premarket rally"
as always buy cheap more then need, other biotech for example AEZx are also high volatile, so who cares? Time to load more
excellent research!
this has happened so often last months with this f...ing stock, climbing strong and fast then going down again, so i´m not longer surprised about it. Have made money with the last big run, but sold to early and bought back to early also and always to expensive, now lurking and collecting and waiting when they release one of those PRs like "have reached the primary endpoint"... or so - then the sky is the limit :o) good luck
it´s very cheap - and management has bought also
Anthera was also mentioned:
http://www.thelifesciencesreport.com/pub/na/14479
Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
HAYWARD, Calif., Nov. 13, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced additional data from its Phase 2b PEARL-SC study presented in a late breaking poster at the 2012 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP). The poster entitled "Blisibimod, an Inhibitor of B cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus," was presented by Dr. Richard Furie, MD, on Tuesday, November 13, 2012. Dr. Furie is Chief of the Division of Rheumatology and Allergy-Clinical Immunology at the North Shore-Long Island Jewish Health System and directs the hospital's Systemic Lupus Erythematosus (SLE) and Autoimmune Disease Treatment Center.
The poster highlights data from the PEARL-SC clinical study including new information regarding treatment effects in the broader modified intent to treat population of lupus patients where 200 mg weekly blisibimod therapy was associated with statistically significant benefits in predefined SLE Responder Index (SRI*) endpoints. Specifically, this new data indicates statistically significant treatment effects using higher thresholds of improvement in disease score (SELENA/SLEDAI** reductions of 7 and 8) including the recently FDA reviewed SRI-8 endpoint to be utilized in the phase 3 CHABLIS-SC clinical studies. These data confirm and expand on previously reported clinical improvements seen in the population of patients to be enrolled in the CHABLIS-SC phase 3 clinical studies. These studies will enroll patients with active disease (SELENA/SLEDAI > 10) who are also receiving corticosteroid therapy at baseline.
As well, the poster highlighted the positive effects of blisibimod on markers of renal disease including proteinuria and antibodies to double stranded DNA.
"PEARL-SC provided a great deal of insight into the treatment effect of blisibimod in patients who continue to have overt clinical manifestations of their disease, such as a rash and joint pain, despite the addition of corticosteroid therapy," said Dr. Furie.
"These results validate our earlier findings in patients with severe disease and provide further confirmation for our choice of study population and endpoint in the CHABLIS-SC Phase 3 development program," said Colin Hislop, MD, Anthera's Senior Vice President and Chief Medical Officer. "These data also provide a sound rationale for our Phase 2 program to examine the utility of blisibimod as a potential treatment for patients' renal disease, such as IgA nephropathy and lupus nephritis and encourage further expansion of inclusion criteria for the CHABLIS-SC2 phase 3 program to include stable presentations of lupus nephritis."
Abstracts can be accessed on the ACR website at http://www.acrannualmeeting.org/. The poster will be available on www.anthera.com.
http://ih.advfn.com/p.php?pid=nmona&article=55003187
doesnt they have planned to reveal something new from todays meeting?